A Study of MORAb-009 in Patients With Solid Tumor
|ClinicalTrials.gov Identifier: NCT01018784|
Recruitment Status : Completed
First Posted : November 25, 2009
Last Update Posted : January 21, 2016
Eisai Co., Ltd.
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||May 2012|
|Study Completion Date :||February 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.